# EDGAR Filing Document

**Accession Number:** 0001580149
**File Stem:** 0001104659-23-031282
**Filing Date:** 2023-3
**Character Count:** 13556
**Document Hash:** 746e78c2f73de1ece6ac8bef9fb4e718
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-031282.hdr.sgml**: 20230310

**ACCESSION NUMBER**: 0001104659-23-031282

**CONFORMED SUBMISSION TYPE**: SC 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230310

**DATE AS OF CHANGE**: 20230310

**GROUP MEMBERS**: TERREN S. PEIZER

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIOVIE INC.
- **CENTRAL INDEX KEY:** 0001580149
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 462510769
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** SC 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90544
- **FILM NUMBER:** 23724717

**BUSINESS ADDRESS:**
- **STREET 1:** 680 W NYE LANE
- **STREET 2:** SUITE 201
- **CITY:** CARSON CITY
- **STATE:** NV
- **ZIP:** 89703
- **BUSINESS PHONE:** 775-888-3162

**MAIL ADDRESS:**
- **STREET 1:** 680 W NYE LANE
- **STREET 2:** SUITE 201
- **CITY:** CARSON CITY
- **STATE:** NV
- **ZIP:** 89703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NANOANTIBIOTICS, INC.
- **DATE OF NAME CHANGE:** 20130625
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Acuitas Group Holdings, LLC
- **CENTRAL INDEX KEY:** 0001797168
- **IRS NUMBER:** 270901060
- **STATE OF INCORPORATION:** CA

**FILING VALUES:**
- **FORM TYPE:** SC 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 2120 COLORADO AVENUE, #230
- **CITY:** SANTA MONICA
- **STATE:** CA
- **ZIP:** 90404
- **BUSINESS PHONE:** 310-444-4321

**MAIL ADDRESS:**
- **STREET 1:** 2120 COLORADO AVENUE, #230
- **CITY:** SANTA MONICA
- **STATE:** CA
- **ZIP:** 90404

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D. C. 20549**

**SCHEDULE 13D**

**Under the Securities Exchange Act of 1934**

**(Amendment No. 9)\***

**BIOVIE INC.**

(Name of Issuer)

**Class A Common Stock, par value $0.0001 per share**

(Title of Class of Securities)

**09074F 207**

(CUSIP Number)

**Terren S. Peizer**

**Acuitas Group Holdings, LLC**

**200 Dorado Beach Drive #3831**

**Dorado, Puerto Rico 00646**

**310-444-4321**

(Name, Address and Telephone Number of Person Authorized

to Receive Notices and Communications)

**March 7, 2023\*\***

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a Statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this Schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ◻

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7(b) for other parties to whom copies are to be sent.

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

\*\*Explanatory Note: The purpose of this Amendment No. 9 to Schedule 13D is to correct the information with respect to the Reporting Persons' beneficial ownership of the Common Stock that was erroneously reported in Amendment No. 8 to Schedule 13D, filed by the Reporting Persons with the SEC on March 7, 2023.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;**CUSIP No.** 09074F 207 | **Page 2** |

---

(1) NAMES OF REPORTING PERSONS Acuitas Group Holdings, LLC

(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ◻ (b) ◻

(3) SEC USE ONLY

(4) SOURCE OF FUNDS (See Instructions) OO

(5) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ◻

(6) CITIZENSHIP OR PLACE OF ORGANIZATION California

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp;(7) | &nbsp;&nbsp; SOLE VOTING POWER<br> 0 |
| &nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp;(8) | &nbsp;&nbsp; SHARED VOTING POWER<br> 30,435,738<sup>+</sup> |
| &nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp;(9) | &nbsp;&nbsp; SOLE DISPOSITIVE POWER<br> 0 |
| &nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp;(10) | &nbsp;&nbsp; SHARED DISPOSITIVE POWER<br> 30,435,738<sup>+</sup> |

---

(11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 30,435,738<sup>+</sup>

(12) CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) ◻

(13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 71.91%\*

(14) TYPE OF REPORTING PERSON (See Instructions) CO

<sup>+</sup> Represents the sum of (i) 23,163,010 shares of the Issuer's Class A common stock ("<u>Common Stock</u>") held directly by Acuitas and (ii) 7,272,728 shares of Common Stock underlying the Warrant previously issued to Acuitas on August 15, 2022.

\* Based on 42,325,296 shares of Common Stock deemed outstanding pursuant to Rule 13d-3(d)(1), calculated as the sum of (i) 34,987,568 shares of Common Stock outstanding as of February 1, 2023, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the SEC on February 10, 2023 (the "<u>Form 10-Q</u>"), (ii) 7,272,728 shares of Common Stock that may be issued to Acuitas upon exercise of the Warrant, and (iii) an aggregate of 65,000 shares of Common Stock underlying options previously granted to Mr. Peizer on November 23, 2022, which options automatically became fully vested and exercisable as of March 2, 2023 pursuant to their terms upon Mr. Peizer's resignation as Chairman of the Board of Directors of the Company.

SCHEDULE 13D

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;**CUSIP No.** 09074F 207 | **Page 3** |

---

(1) NAMES OF REPORTING PERSONS Terren S. Peizer

(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ◻ (b) ◻

(3) SEC USE ONLY

(4) SOURCE OF FUNDS (See Instructions) OO

(5) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ◻

(6) CITIZENSHIP OR PLACE OF ORGANIZATION United States of America

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp;(7) | SOLE VOTING POWER<br> 30,503,938<sup>++</sup> |
| &nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp;(8) | &nbsp;&nbsp; SHARED VOTING POWER<br> 0 |
| &nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp;(9) | &nbsp;&nbsp; SOLE DISPOSITIVE POWER<br> 30,503,938<sup>++</sup> |
| &nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp;(10) | &nbsp;&nbsp; SHARED DISPOSITIVE POWER<br> 0 |

---

(11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 30,503,938<sup>++</sup>

(12) CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (See Instructions) ◻

(13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 72.07%\*

(14) TYPE OF REPORTING PERSON (See Instructions) HC; IN

---

| | |
|:---|:---|
| <sup>++</sup> | Represents the sum of (i) 23,163,010 shares of Common Stock held directly by Acuitas, (ii) 3,200 shares of Common Stock held directly by Mr. Peizer, (iii) 7,272,728 shares of Common Stock underlying the Warrant previously issued to Acuitas on August 15, 2022, and (iv) an aggregate of 65,000 shares of Common Stock underlying options previously granted to Mr. Peizer on November 23, 2022, which options automatically became fully vested and exercisable as of March 2, 2023 pursuant to their terms upon Mr. Peizer's resignation as Chairman of the Board of Directors of the Company.<br>|
| \* | Based on 42,325,296 shares of Common Stock deemed outstanding pursuant to Rule 13d-3(d)(1), calculated as the sum of (i) 34,987,568 shares of Common Stock outstanding as of February 1, 2023, as reported in the Form 10-Q, (ii) 7,272,728 shares of Common Stock that may be issued to Acuitas upon exercise of the Warrant, and (iii) an aggregate of 65,000 shares of Common Stock underlying options previously granted to Mr. Peizer on November 23, 2022, which options automatically became fully vested and exercisable as of March 2, 2023. |

---

**Amendment No. 9 to SCHEDULE 13D**

**Explanatory Note**: The purpose of this Amendment No. 9 to Schedule 13D is to correct the information with respect to the Reporting Persons' beneficial ownership of the Common Stock that was erroneously reported in Amendment No. 8 to Schedule 13D, filed by the Reporting Persons with the SEC on March 7, 2023.

This Amendment No. 9 to Schedule 13D (this "<u>Amendment</u>") amends and supplements the Schedule 13D previously filed by Acuitas Group Holdings, LLC, a California limited liability company ("<u>Acuitas</u>"), and Terren S. Peizer ("<u>Mr. Peizer</u>" and, together with Acuitas, the "<u>Reporting Persons</u>") on July 3, 2018, as amended by Amendment No. 1 filed on September 25, 2019, Amendment No. 2 filed on September 23, 2020, Amendment No. 3 filed on April 27, 2021, Amendment No. 4 filed on May 10, 2021, Amendment No. 5 filed on June 11, 2021, Amendment No. 6 filed on July 15, 2022, Amendment No. 7 to Schedule 13D filed on August 16, 2022, and Amendment No. 8 to Schedule 13D filed on March 7, 2023 (as so amended, the "<u>Original Statement</u>" and, as amended and supplemented by this Amendment, the "<u>Statement</u>"), relating to the Class A common stock, par value $0.0001 per share ("<u>Common Stock</u>"), of BioVie Inc., a Nevada corporation (the "<u>Company</u>" or "<u>Issuer</u>"). Except as specifically amended by this Amendment, items in the Original Statement are unchanged. Capitalized terms used herein that are not defined have the meaning ascribed to them in the Original Statement.

---

| | |
|:---|:---|
| **ITEM 5.** | **INTEREST IN SECURITIES OF THE ISSUER** |

---

Items 5(a) and (b) of the Statement are hereby amended and restated as follows:

"(a) and (b)

All percentages of shares of Common Stock outstanding contained herein are based on 42,325,296 shares of Common Stock deemed outstanding pursuant to Rule 13d-3(d)(1), calculated as the sum of (i) 34,987,568 shares of Common Stock outstanding as of February 1, 2023, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the SEC on February 10, 2023, (ii) 7,272,728 shares of Common Stock that may be issued upon the exercise of the Warrant previously issued to Acuitas on August 15, 2022, as previously described in Item 4 of this Statement, and (iii) an aggregate of 65,000 shares of Common Stock issuable upon the exercise of options previously granted to Mr. Peizer on November 23, 2022, which options automatically became fully vested and exercisable as of March 2, 2023 pursuant to their terms upon Mr. Peizer's resignation as Chairman of the Board of Directors of the Company.

As of March 8, 2023, Acuitas may be deemed to have beneficial ownership of 30,435,738 shares of Common Stock, representing the sum of (i) 23,163,010 shares of Common Stock held directly by Acuitas and (ii) 7,272,728 shares of Common Stock that may be issued to Acuitas upon the exercise of the Warrant. The shares of Common Stock beneficially owned by Acuitas as of the date hereof represents approximately 71.91% of the total outstanding shares. Acuitas may be deemed to share the power to vote or direct the vote and dispose or direct the disposition of all 30,435,738 shares with Mr. Peizer.

As of March 8, 2023, Mr. Peizer may be deemed to have beneficial ownership of 30,503,938 shares of Common Stock, representing the sum of (i) 23,163,010 shares of Common Stock held directly by Acuitas, (ii) 3,200 shares of Common Stock held directly by Mr. Peizer, (iii) 7,272,728 shares of Common Stock that may be issued to Acuitas upon the exercise of the Warrant, and (iv) an aggregate of 65,000 shares of Common Stock underlying options previously granted to Mr. Peizer on November 23, 2022, which options automatically became fully vested and exercisable as of March 2, 2023 pursuant to their terms upon Mr. Peizer's resignation as Chairman of the Board of Directors of the Company. The shares of Common Stock beneficially owned by Mr. Peizer as of the date hereof represents approximately 72.07% of the total outstanding shares. Mr. Peizer may be deemed to have the sole power to vote or direct the vote and dispose or direct the disposition of all of the 30,503,938 shares."

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: March 10, 2023

---

| | |
|:---|:---|
| **ACUITAS GROUP HOLDINGS, LLC** | **ACUITAS GROUP HOLDINGS, LLC** |
| By: | /s/ Terren S. Peizer |
|  | Terren S. Peizer, Chairman |
| /s/ Terren S. Peizer | /s/ Terren S. Peizer |
| Terren S. Peizer | Terren S. Peizer |

---